July 27, 2020 – A vaccine developed by the US National Institutes of Health and Moderna Inc has entered the final stages of testing, the Associated press reported on Monday.
To see if the vaccine will protect people from the virus, 30,000 volunteers will randomly receive both doses of the vaccine or a placebo.
Participants will be followed to see which group is infected.
“Unfortunately for the United States of America, we currently have a lot of infections,” Dr. Anthony Fauci of the NIH told the AP.
According to Moderna, the vaccination has been tested in Savannah, Georgia and will be administered at more than 80 sites across the country.
It is just one of the many vaccines under development around the world. Further trials are underway in China and Britain, and final testing has started in Brazil and other countries.
Before a vaccine can be approved in the United States, it must be tested here. Until the fall, the COVID-19 Prevention Network will test new vaccines – each with 30,000 volunteers, the AP Remarks.
These tests will determine which vaccine works best and is the safest. Vaccines from Johnson & Johnson and Novavax and Pfizer Inc. all need to be tested.
It usually takes years to develop a new vaccine, but experts are rushing to find an effective vaccine that can curb the pandemic.
“We all feel so helpless right now. There is little we can do to combat this virus. And just being able to participate in this trial made me feel like I was doing something, ”said Jennifer Haller, a Seattle volunteer from Seattle. said to AP. “Be prepared for lots of questions from friends and family about how this is going, and lots of thanks.”
In early trials, the vaccine boosted the immune system in a way that should be protective. Some side effects, such as short fever, chills and pain at the injection site have been seen. These results were also observed in the other vaccines planned for testing.
If the vaccine passes the test, it will be months before it can reach the general public.
The first doses will most likely be given to those most exposed to the virus, the AP said.
“We are optimistic, cautiously optimistic” that the vaccine will work and that “by the end of the year” the data will prove it, Dr. Stephen Hoge, president of Massachusetts-based Moderna, told a subcommittee of the Room last week. AP reported.
“I’m not sure what the odds are that this is exactly the right vaccine. But thank goodness there are so many others fighting this right now,” Haller said.
Our sincere thanks to